Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatment of such disease
US12140594B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 7, 2023 |
| Grant date | Nov 12, 2024 |
| Priority date | — |
| Expiry date | Jul 7, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of βig-h3 protein in a blood sample wherein the serum level of βig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that βig-h3 can be directly detected in the blood sample and βig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of βig-h3 protein, for use in the treatment of PDAC. The inventors found that βig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing βig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response. Thus, neutralizing βig-h3 which acts as a novel immunological check-point target in PDAC therefore allows to restore beneficial anti-tumor immunity in PDAC.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.